February 27, 2019
Bristol-Myers Squibb said on February 26 that it has filed an application in Japan seeking approval for its cancer drug Empliciti (elotuzumab) for use in a new triplet combination therapy with Pomalyst (pomalidomide) and dexamethasone for the treatment of relapsed/refractory...read more